LakeShore Biopharma Co Gross Profit

The latest gross profit for LSB is $250M as of March 2024. That compares with $42M in the prior-year period — up 505.0% year over year. That is below the sector sector average of $790M. Investors often review this figure alongside LakeShore Biopharma Co's historical trend and sector peers before judging valuation or financial health.

Over the past year, LSB's gross profit moved from $42M to $250M — a 505.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in LakeShore Biopharma Co's operating scale or balance-sheet position.

Against its sector companies, LSB currently prints $250M for gross profit, while the sector average sits near $790M. That is roughly 67.8% below the sector mean. Large gaps often invite a closer look at LakeShore Biopharma Co's growth, margins, and balance sheet.

A gross profit figure of $250M for LSB is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $790M. Explore the charts below for those layers of context.

After noting LSB's gross profit ($250M), review year-over-year change from $42M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.